Dr. Rippee speaks about enrolling patients in Oxeia’s Phase 2 Clinical Trial for Concussions on KU’s Morning Medical Update

Written By John Hauschildt

Dr. Michael Rippee, Medical Director for the Center for Concussion Management and a Sports Neurologist at the University of Kansas Medical Center, talks about enrolling participants and the exciting science behind Oxeia’s Phase 2 Concussion Trial.

John Hauschildt https://www.RumDoodle.com
Previous

KUMC: The University of Kansas Health System Center for Concussion Management will hold its 4th Annual Symposium on August 6, 2022.
Next

Clinical Trial For Concussion Therapeutic on Recovery Now with Kim Justus